Showing 5031-5040 of 8162 results for "".
- Dove Launches DermaSeries Product Line for Dry Skin Plus Companion Campaignhttps://practicaldermatology.com/news/dove-launches-dermaseries-product-line-for-dry-skin-plus-companion-campaign/2457904/Dove is rolling out NEW Dove DermaSeries, a completely hypoallergenic and fragrance-free range of cleansers and lotions formulated especially for the driest skin. A companion campaign --
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Dr. Brandt Skincare Rolls Out Two New Productshttps://practicaldermatology.com/news/dr-brandt-skincare-rolls-out-two-new-products/2457909/Dr. Brandt skincare is introducing Hydro Biotic Recovery Sleeping Mask and Antioxidant Water Booster. The new sleeping mask is powered by Dr. Brandt Skincare's Biotic Balancing Complex, an oligosaccharide and yogurt powder that helps restore n
- Meet TempSure™ Envi from Hologic's Cynosure Divisionhttps://practicaldermatology.com/news/meet-tempsure-envi-from-hologics-cynosure-division/2457915/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and impro
- Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acnehttps://practicaldermatology.com/news/retin-a-micro-gel-microsphere-006-now-available-from-ortho-dermatologics-to-treat-acne/2457914/Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgar
- GlobalData: Promising Future Forecasted for Dupixenthttps://practicaldermatology.com/news/globaldata-promising-future-forecasted-for-dupixent/2457917/Regeneron Pharmaceuticals and Sanofi Genzyme’s Dupixent is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis on the market, according to
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv